HomeAbout

TL;DR CNBC


Pfizer to end development of experimental obesity pill due to elevated liver enzymes - TL;DR CNBC

Pfizer to end development of experimental obesity pill due to elevated liver enzymes

Publishing timestamp: 2023-06-26 12:35:25


Summary

Pfizer is stopping development of its obesity and diabetes pill lotiglipron due to liver enzyme issues, focusing on danuglipron instead. The weight loss industry is seeing a gold rush with new drugs, but questions remain about accessibility and long-term effectiveness. Analysts believe Eli Lilly's pill may have an edge over Pfizer's danuglipron.


Sentiment: MIXED

Tickers: LLYPFENOVO.B-DK

Keywords: size and weight discriminationbreaking newsbusinessbiotech and pharmaceuticalslilly drnhealth care industrybiotechnologysciencepfizer incbusiness newsweight managementpharmaceuticalsnovo nordisk a/s

Source: https://www.cnbc.com/2023/06/26/pfizer-to-end-development-of-experimental-obesity-pill-lotiglipron.html


Developed by Leo Phan